Neurology International Open 2017; 01(03): E224-E231
DOI: 10.1055/s-0043-113034
Review
© Georg Thieme Verlag KG Stuttgart · New York

Update on Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)

Jan Hoffmann
1   Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg
,
Arne May
1   Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg
› Author Affiliations
Further Information

Publication History

Publication Date:
13 September 2017 (online)

Abstract

Idiopathic intracranial hypertension is characterized by an increase of intracranial pressure of unknown etiology. The clinical presentation is dominated by progressive visual disturbances, which are commonly the result of a papilledema, headache and cranial nerve palsies. Clinical studies have revealed over the past years that the syndrome may also be associated with olfactory disturbances, cognitive deficits and a pulsatile tinnitus.

The underlying pathomechanism is probably based on a disturbance of venous outflow, which causes a reduced absorption of cerebrospinal fluid that results in an increase of cerebrospinal fluid pressure. It remains unclear if the venous outflow disturbance results from the overweight-induced increase of intrathoracic pressure, the presence of sinus vein stenoses or both conditions. Recently hormonal factors have also been discussed, but the mechanisms behind a potential influence on intracranial pressure remain unclear.

Treatment of idiopathic intracranial hypertension relies mainly on an effective body weight reduction and medication with carboanhydrase inhibitors, which can reduce the production of cerebrospinal fluid and body weight. Results of the first randomized, placebo-controlled trial as well as a 12-month follow-up show that acetazolamide effectively reduces papilledema, visual disturbances and headache in idiopathic intracranial hypertension. In contrast, the evidence for the carboanhydrase inhibitors topiramate and furosemide still relies on open-label trials, because double-blind, placebo-controlled trials for their efficacy in idiopathic intracranial hypertension do not exist. In addition to the treatment with carboanhydrase inhibitors, increasing evidence suggests that the somatostatin analog octreotide may be effective in the treatment of idiopathic intracranial hypertension, but to date no randomized, double-blind, placebo-controlled trials exist to confirm this observation.

 
  • References

  • 1 Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 2013; 81: 1159-1165
  • 2 Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin 2014; 32: 363-396
  • 3 Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol 1988; 45: 875-877
  • 4 Radhakrishnan K, Ahlskog JE, Cross SA. et al. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol 1993; 50: 78-80
  • 5 Hoffmann J, Goadsby PJ. Update on intracranial hypertension and hypotension. Curr Opin Neurol 2013; 26: 240-247
  • 6 Hoffmann J. Headache Attributed to Intracranial Hypertension and Hypotension. In: Mitsikostas DD, Pameleire K. Hrsg Pharmacological Management of Headaches. 1. Aufl. Springer ; 2015: 189-205
  • 7 Wall M, Kupersmith MJ, Kieburtz KD. et al. The idiopathic intracranial hypertension treatment trial: Clinical profile at baseline. JAMA Neurol 2014; 71: 693-701
  • 8 Daniels AB, Liu GT, Volpe NJ. et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 2007; 143: 635-641
  • 9 Almarzouqi SJ, Morgan ML, Lee AG. Idiopathic intracranial hypertension in the Middle East: A growing concern. Saudi J Ophtamlol 2015; 29: 26-31
  • 10 Wall M. Idiopathic intracranial hypertension. Neurol Clin 2010; 28: 593-617
  • 11 Ko MW, Liu GT. Pediatric idiopathic intracranial hypertension (pseudotumor cerebri). Horm Res Paediatr 2010; 74: 381-389
  • 12 Cinciripini GS, Donahue S, Borchert MS. Idiopathic intracranial hypertension in prepubertal pediatric patients: Characteristics, treatment, and outcome. Am J Ophthalmol 1999; 127: 178-182
  • 13 Sheldon CA, Paley GL, Xiao R. et al. Pediatric idiopathic intracranial hypertension: Age, gender, and anthropometric features at diagnosis in a large, retrospective, multisite cohort. Ophthalmology 2016; 123: 2424-2431
  • 14 Mendelson CR, Simpson ER. Regulation of estrogen biosynthesis by human adipose cells in vitro. Mol Cell Endocrinol 1987; 52: 169-176
  • 15 Markey KA, Uldall M, Botfield H. et al. Idiopathic intracranial hypertension, hormones, and 11beta-hydroxysteroid dehydrogenases. J Pain Res 2016; 9: 223-232
  • 16 Ball AK, Sinclair AJ, Curnow SJ. et al. Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): Evidence for hypothalamic leptin resistance?. Clin Endocrinol (Oxf) 2017; 37: 113-121
  • 17 Lampl Y, Eshel Y, Kessler A. et al. Serum leptin level in women with idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2002; 72: 642-643
  • 18 Dinkin MJ, Patsalides A. Venous sinus stenting in idiopathic intracranial hypertension: Results of a prospective trial. J Neuroophthalmol 2017; 37: 113-121
  • 19 Farb RI, Vanek I, Scott JN. et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 2003; 60: 1418-1424
  • 20 Ahmed RM, Wilkinson M, Parker GD. et al. Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions. AJNR Am J Neuroradiol 2011; 32: 1408-1414
  • 21 Bedford THB. The effect of increased intracranial venous pressure on the pressure of the cerebrospinal fluid. Brain 1935; 58: 427-447
  • 22 Giuseffi V, Wall M, Siegel PZ. et al. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): A case control study. Neurology 1991; 41: 239
  • 23 Headache classification committee of the international headache society . The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013; 33: 629-808
  • 24 Yri HM, Rönnbäck C, Wegener M. et al. The course of headache in idiopathic intracranial hypertension: A 12-month prospective follow-up study. Eur J Neurol 2014; 21: 1458-1464
  • 25 Wall M. The headache profile of idiopathic intracranial hypertension. Cephalalgia 1990; 10: 331-335
  • 26 Wall M, White 2nd WN. Asymmetric papilledema in idiopathic intracranial hypertension: Prospective interocular comparison of sensory visual function. Invest Ophthalmol Vis Sci 1998; 39: 134-142
  • 27 Keltner JL, Johnson CA, Cello KE. et al. Baseline visual field findings in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest Ophthalmol Vis Sci 2014; 55: 3200-3207
  • 28 Bidot S, Bruce BB, Saindane AM. et al. Asymmetric papilledema in idiopathic intracranial hypertension. J Neuroophthalmol 2015; 35: 31-36
  • 29 Jonas JB, Ritch R, Panda-Jonas S. Cerebrospinal fluid pressure in the pathogenesis of glaucoma. In: Giacinto B, Carlo N. eds. New Trends in Basic and Clinical Research of Glaucoma: A Neurodegenerative Disease of the Visual System Part B (Progress in Brain Research 225). Amsterdam, . Elsevier; 2015: 33-47
  • 30 Hayreh SS. Pathogenesis of optic disc edema in raised intracranial pressure. Prog Retin Eye Res 2016; 50: 108-144
  • 31 Schmidt C, Wiener E, Lüdemann L. et al. Does IIH alter brain microstructures? – A DTI-based approach. Headache 2017; 57: 746-755
  • 32 Hoffmann J, Schmidt C, Kunte H. et al. Volumetric assessment of optic nerve sheath and hypophysis in idiopathic intracranial hypertension. AJNR Am J Neuroradiol 2014; 35: 513-518
  • 33 Hoffmann J, Huppertz HJ, Schmidt C. et al. Morphometric and volumetric MRI changes in idiopathic intracranial hypertension. Cephalalgia 2013; 33: 1075-1084
  • 34 Digre KB, Nakamoto BK, Warner JE. et al. A comparison of idiopathic intracranial hypertension with and without papilledema. Headache 2009; 49: 185-193
  • 35 Wall M, Falardeau J, Fletcher WA. et al. Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension. Neurology 2015; 85: 799-805
  • 36 Wall M, Thurtell MJ. Optic disc haemorrhages at baseline as a risk factor for poor outcome in the idiopathic intracranial hypertension treatment trial. Br J Ophthalmol 2017 doi:10.1136/bjophthalmol-2016-309852
  • 37 Kaufhold F, Kadas EM, Schmidt C. et al. Optic nerve head quantification in idiopathic intracranial hypertension by spectral domain OCT. PLoS One 2012; 7: e36965
  • 38 OCT Sub-Study Committee for the Nordic Idiopathic Intracranial Hypertension Study . Baseline OCT Measurements in the Idiopathic Intracranial Hypertension Treatment Trial, Part I: Quality Control, Comparisons, and VariabilityBaseline OCT Measurements in IIHTT, Part I. Invest Ophthalmol Vis Sci 2014; 55: 8180-8188
  • 39 Rebolleda G, Muñoz-Negrete FJ. Follow-up of mild papilledema in idiopathic intracranial hypertension with optical coherence tomography. Invest Ophthalmol Vis Sci 2009; 50: 5197-5200
  • 40 Lochner P, Brigo F, Zedde ML. et al. Feasibility and usefulness of ultrasonography in idiopathic intracranial hypertension or secondary intracranial hypertension. BMC Neurology 2016; 16: 85
  • 41 Moretti R, Pizzi B, Cassini F. et al. Reliability of optic nerve ultrasound for the evaluation of patients with spontaneous intracranial hemorrhage. Neurocrit Care 2009; 11: 406-410
  • 42 Geeraerts T, Merceron S, Benhamou D. et al. Non-invasive assessment of intracranial pressure using ocular sonography in neurocritical care patients. Intensive Care Med 2008; 34: 2062-2067
  • 43 Bäuerle J, Nedelmann M. Sonographic assessment of the optic nerve sheath in idiopathic intracranial hypertension. J Neurol 2011; 258: 2014-2019
  • 44 McCammon A, Kaufman HH, DSears ES. Transient oculomotor paralysis in pseudotumor cerebri. Neurology 1981; 31: 182-184
  • 45 Lee AG. Fourth nerve palsy in pseudotumor cerebri. Strabismus 1995; 3: 57-59
  • 46 Davenport RJ, Will RG, Galloway PJ. Isolated intracranial hypertension presenting with trigeminal neuropathy. J Neurol Neurosurg Psychiatry 1994; 57: 381
  • 47 Capobianco DJ, Brazis PW, Cheshire WP. Idiopathic intracranial hypertension and seventh nerve palsy. Headache 1997; 37: 286-288
  • 48 Soroken C, Lacroix L, Korff CM. Combined VIth and VIIth nerve palsy: Consider idiopathic intracranial hypertension!. Eur J Paed Neurol 2016; 20: 336-338
  • 49 Davie C, Kennedy P, Katifi HA. Seventh nerve palsy as a false localising sign. J Neurol Neurosurg Psychiatry 1992; 55: 510-511
  • 50 Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 Pt 1A 155-180
  • 51 Reid JE, Reem RE, Aylward SC. et al. Sixth nerve palsy in paediatric intracranial hypertension. Neuro-ophthalmology 2016; 40: 23-27
  • 52 Khoo KF, Kunte H. Olfactory dysfunction in patients with idiopathic intracranial hypertension. Neurology 2014; 82: 189
  • 53 Kunte H, Schmidt F, Kronenberg G. et al. Olfactory dysfunction in patients with idiopathic intracranial hypertension. Neurology 2013; 81: 379-382
  • 54 Schmidt C, Wiener E, Hoffmann J. et al. Structural olfactory nerve changes in patients suffering from idiopathic intracranial hypertension. PLoS One 2012; 7: e35221
  • 55 Goektas O, Fleiner F, Sedlmaier B. et al. Correlation of olfactory dysfunction of different etiologies in MRI and comparison with subjective and objective olfactometry. Eur J Radiol 2009; 71: 469-473
  • 56 Hummel T, Urbig A, Huart C. et al. Volume of olfactory bulb and depth of olfactory sulcus in 378 consecutive patients with olfactory loss. J Neurol 2015; 262: 1046-1051
  • 57 Buschhüter D, Smitka M, Puschmann S. et al. Correlation between olfactory bulb volume and olfactory function. Neuroimage 2008; 42: 498-502
  • 58 Becker N, Kronenberg G, Harms L et al. Rapid improvement of olfaction after lumbar puncture in a patient with idiopathic intracranial hypertension. Headache 2016 doi: 10.1111/head.12802
  • 59 Kaplan CP, Miner ME, McGregor JM. Pseudotumour cerebri: Risk for cognitive impairment?. Brain Inj 1997; 11: 293-303
  • 60 Sorensen PS, Thomsen AM, Gjerris F. Persistent disturbances of cognitive functions in patients with pseudotumor cerebri. Acta Neurol Scand 1986; 73: 264-268
  • 61 Kharkar S, Hernandez R, Batra S. et al. Cognitive impairment in patients with pseudotumor cerebri syndrome. Behav Neurol 2011; 24: 143-148
  • 62 Yri HM, Fagerlund B, Forchhammer HB. et al. Cognitive function in idiopathic intracranial hypertension: A prospective case–control study. BMJ Open 2014; 4: e004376
  • 63 Bono F, Salvino D, Tallarico T. et al. Abnormal pressure waves in headache sufferers with bilateral transverse sinus stenosis. Cephalalgia 2010; 30: 1419-1425
  • 64 Torbey MT, Geocadin RG, Razumovsky AY. et al. Utility of CSF pressure monitoring to identify idiopathic intracranial hypertension without papilledema in patients with chronic daily headache. Cephalalgia 2004; 24: 495-502
  • 65 Toma AK, Tarnaris A, Kitchen ND. et al. Continuous intracranial pressure monitoring in pseudotumour cerebri: Single centre experience. Br J Neurosurg 2010; 24: 584-588
  • 66 Agid R, Farb RI, Willinsky RA. et al. Idiopathic intracranial hypertension: The validity of cross-sectional neuroimaging signs. Neuroradiology 2006; 48: 521-527
  • 67 Degnan AJ, Levy LM. Pseudotumor Cerebri: Brief review of clinical syndrome and imaging findings. AJNR Am J Neuroradiol 2011; 32: 1986-1993
  • 68 Maralani PJ, Hassanlou M, Torres C. et al. Accuracy of brain imaging in the diagnosis of idiopathic intracranial hypertension. Clin Radiol 2012; 67: 656-663
  • 69 Sinclair AJ, Burdon MA, Nightingale PG. et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010; 341: c2701
  • 70 Ko MW, Chang SC, Ridha MA. et al. Weight gain and recurrence in idiopathic intracranial hypertension: A case-control study. Neurology 2011; 76: 1564-1567
  • 71 Manfield JH, Yu KK-H, Efthimiou E. et al. Bariatric surgery or non-surgical weight loss for idiopathic intracranial hypertension? a systematic review and comparison of meta-analyses. Obesity Surgery 2017; 27: 513-521
  • 72 Johnston I, Paterson A. Beningn intracranial hypertension: II. CSF pressure and and circulation. Brain 1974; 97: 301-312
  • 73 Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012; 83: 488-494
  • 74 Scoffings DJ, Pickard JD, Higgins JN. Resolution of transverse sinus stenoses immediately after CSF withdrawal in idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2007; 78: 911-912
  • 75 Bateman GA, Stevens SA, Stimpson J. A mathematical model of idiopathic intracranial hypertension incorporating increased arterial inflow and variable venous outflow collapsibility. J Neurosurg 2009; 110: 446-456
  • 76 De Simone R, Marano E, Fiorillo C. et al. Sudden re-opening of collapsed transverse sinuses and longstanding clinical remission after a single lumbar puncture in a case of idiopathic intracranial hypertension. Pathogenetic implications. Neurol Sci 2005; 25: 342-344
  • 77 Damkier HH, Brown PD, Praetorius J. Cerebrospinal fluid secretion by the choroid plexus. Physiol Rev 2013; 93: 1847-1892
  • 78 Rubin RC, Henderson ES, Ommaya AK. et al. The production of cerebrospinal fluid in man and its modification by acetazolamide. J Neurosurg 1966; 25: 430-436
  • 79 Gucer G, Viernstein L. Long-term intracranial pressure recording in the management of pseudotumor cerebri. J Neurosurg 1978; 49: 256-263
  • 80 Celebisoy N, Gokcay F, Sirin H. et al. Treatment of idiopathic intracranial hypertension: Topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007; 116: 322-327
  • 81 Ball AK, Howman A, Wheatley K. et al. A randomised controlled trial of treatment for idiopathic intracranial hypertension. J Neurol 2011; 258: 874-881
  • 82 Wall M, McDermott MP, Kieburtz KD. et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: The idiopathic intracranial hypertension treatment trial. JAMA 2014; 311: 1641-1651
  • 83 Digre KB, Bruce BB, McDermott MP. et al. Quality of life in idiopathic intracranial hypertension at diagnosis: IIH Treatment Trial results. Neurology 2015; 84: 2449-2456
  • 84 Wall M, Kupersmith MJ, Thurtell MJ et al. The longitudinal idiopathic intracranial hypertension trial: outcomes from months 6 - 12. Am J Ophthalmol 2017; 176: 102–107
  • 85 Sinclair AJ, Woolley R, Mollan SP. Idiopathic intracranial hypertension. JAMA 2014; 312: 1059-1060
  • 86 Shah VA, Fung S, Shahbaz R. et al. Idiopathic intracranial hypertension. Ophthalmology 2007; 114: 617
  • 87 Loring DW, Williamson DJ, Meador KJ. et al. Topiramate dose effects on cognition: A randomized double-blind study. Neurology 2011; 76: 131-137
  • 88 Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: A patent and literature review (2005 - 2013). Expert Opin Ther Pat 2013; 23: 681-691
  • 89 Deftereos SN, Panagopoulos G, Georgonikou D. et al. Treatment of idiopathic intracranial hypertension: Is there a place for octreotide?. Cephalalgia 2011; 31: 1679-1680
  • 90 House PM, Stodieck SRG. Octreotide: The IIH therapy beyond weight loss, carbonic anhydrase inhibitors, lumbar punctures and surgical/interventional treatments. Clin Neurol Neurosurg 2016; 150: 181-184
  • 91 Panagopoulos GN, Deftereos SN, Tagaris GA et al. Octreotide: a therapeutic option for idiopathic intracranial hypertension. Neurol Neurophysiol Neurosci 2007; 1:
  • 92 Antaraki A, Piadites G, Vergados J. et al. Octreotide in benign intracranial hypertension. Lancet 1993; 342: 1170
  • 93 Williams G, Ball JA, Lawson RA. et al. Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumours. Br Med J Clin Res Ed 1987; 295: 247-248
  • 94 Malozowski S, Tanner LA, Wysowski D. et al. Growth hormone, insulin-like growth factor i, and benign intracranial hypertension. N Engl J Med 1993; 329: 665-666
  • 95 Owler BK, Parker G, Halmagyi GM. et al. Cranial venous outflow obstruction and pseudotumor Cerebri syndrome. Adv Tech Stand Neurosurg 2005; 30: 107-174
  • 96 Owler BK, Parker G, Halmagyi GM. et al. Pseudotumor cerebri syndrome: venous sinus obstruction and its treatment with stent placement. J Neurosurg 2003; 98: 1045-1055
  • 97 Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2005; CD003434
  • 98 Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol 1993; 111: 632-635
  • 99 Kelman SE, Heaps R, Wolf A. et al. Optic nerve decompression surgery improves visual function in patients with pseudotumor cerebri. Neurosurgery 1992; 30: 391-395
  • 100 Menger RP, Connor Jr. DE, Thakur JD. et al. A comparison of lumboperitoneal and ventriculoperitoneal shunting for idiopathic intracranial hypertension: An analysis of economic impact and complications using the Nationwide Inpatient Sample. Neurosurg Focus 2014; 37: E4
  • 101 Sinclair AJ, Kuruvath S, Sen D. et al. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia 2011; 31: 1627-1633
  • 102 Batra R, Sinclair A. Idiopathic intracranial hypertension; Research progress and emerging themes. J Neurol 2014; 261: 451-460